Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biological and Pharmaceutical Bulletin

• Publication date

  2015-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1248/bpb.b14-00622PMID 26235575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Role of Human Equilibrative Nucleoside Transporter 1 on the Cellular Transport of the DNA Methyltransferase Inhibitors 5-Azacytidine and CP-4200 in Human Leukemia Cells

  2013cited by this paper
• Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

  2013cited by this paper
• Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine

  2012cited by this paper
• Nucleoside transporters: biological insights and therapeutic applications.

  2012cited by this paper
• Epigenetics of colorectal cancer.

  2012cited by this paper
• ENT1, a Ribavirin Transporter, Plays a Pivotal Role in Antiviral Efficacy of Ribavirin in a Hepatitis C Virus Replication Cell System

  2012cited by this paper
• Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.

  2012cited by this paper
• Cancer Stem Cells in Colorectal Cancer: Genetic and Epigenetic Changes.

  2012cited by this paper
• Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.

  2011cited by this paper
• The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2’deoxycytidine (decitabine) are differentially regulated by cell cycle progression

  2011cited by this paper
• Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

  2008cited by this paper
• Evolution of decitabine development

  2008cited by this paper
• Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15

  2007cited by this paper
• 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms.

  2005cited by this paper
• Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters.

  2005cited by this paper
• Membrane Transporters and Channels

  2004cited by this paper
• Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.

  2004cited by this paper
• Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines

  2003cited by this paper
• Kinetic and Pharmacological Properties of Cloned Human Equilibrative Nucleoside Transporters, ENT1 and ENT2, Stably Expressed in Nucleoside Transporter-deficient PK15 Cells

  2000cited by this paper
• Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

  2000cited by this paper
• Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

  1998cited by this paper
• Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.

  1998cited by this paper
• Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

  1998cited by this paper
• Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.

  1995cited by this paper
• Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

  1995cited by this paper
• Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.

  1982cited by this paper

• Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition

  2025cites this paper
• Effects of DNA Methylation Inhibitors on Molecular and Structural Changes in Chromatin Organization in Leukemia Cells

  2025cites this paper
• Human equilibrative nucleoside transporter 1 and concentrative nucleoside transporter 1 in colorectal cancer: What do we know? A systematic review.

  2025cites this paper
• Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine

  2023cites this paper
• In vitro interaction of tetrahydrouridine with key human nucleoside transporters.

  2023cites this paper
• DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

  2023cites this paper
• Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol

  2023cites this paper
• Platelets for advanced drug delivery in cancer

  2023cites this paper
• Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.

  2022cites this paper
• Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients

  2022cites this paper
• The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine

  2022cites this paper
• Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

  2021cites this paper
• Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

  2021cites this paper
• Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1

  2021influential citation
• Model Analysis of the Apparent Saturation Kinetics of Purine Nucleobase Uptake in Cells co-Expressing Transporter and Metabolic Enzyme

  2021cites this paper
• Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles

  2020cites this paper
• Numerical analysis of apparent decitabine uptake in HCT116 cells: Incorporation of a bidirectional first-order kinetic parameter for ENT1 transport and Michaelis-Menten parameters for subsequent phosphorylation.

  2019cites this paper
• Intermediate-term memory in Aplysia involves neurotrophin signaling, transcription, and DNA methylation

  2018cites this paper
• Inhibitor selectivity of CNTs and ENTs

  2018influential citation
• Differential expression of hENT 1 and hENT 2 in colon cancer cell lines

  2017cites this paper
• Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.

  2017cites this paper
• Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

  2017cites this paper
• Differential expression of hENT1 and hENT2 in colon cancer cell lines.

  2017cites this paper
• Knockdown of ATPase family AAA domain-containing protein 2 inhibits the proliferation of colorectal cancer cells in vitro and in vivo

  2016cites this paper